tbuckley/cabot-search huggingface dataset:
Evaluating the clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer (PCa).
Authors: Ahmad Zarzour, Alicia K. Morgans, Phillip Lee Palmbos, Borko Jovanovic, Scott A. Tomlins, David James VanderWeele, Ximing J Yang, Edward M. Schaeffer, Roohollah Sharifi, Joshua J Meeks, Sarki Abdulkadir, Maha H. A. Hussain
Journal: Journal of Clinical Oncology (2019)

TPS333 Background: Although PCa incidence has stabilized or decreased in most age groups, the incidence of metastatic disease has increased among men 50-69 years old. The incidence of fatal PCa has decreased for most age groups, it has remained unchanged in men under 55 years old. These observations are supported by data from 3 randomized trials. In S9346 in newly diagnosed M1, 18% of men (all-comers N = 3040) were ≤ 60 years. A significant percentage of younger men enrolled in CHAARTED had de-novo metastases at diagnosis; among 575 patients without prior local therapy, the median age was 62 years, and among men &lt; 60 years old (n = 274), 80.3% (n = 220) had de novo metastatic disease. Lastly, in S9921 (N = 983) 15% of men ≤ 60 years had pN1 disease at enrollment. A significant proportion of men with metastatic disease progress to castration -resistance within a short interval of initiating androgen-deprivation therapy (ADT) ± docetaxel or abiraterone for metastatic hormone sensitive PCa. Pivotal studies have described genetic abnormalities in aggressive localized or end stage prostate cancers, but early-onset cases and those with early progression on systemic therapy are not included or are under-represented in these studies. Methods: The primary objective of this multi-institutional trial is to characterize the clinical, environmental, genetic and genomic features of high-risk advanced PCa: Cohort 1: men ≤ 60 years old with N1 or M1 at diagnosis or who develop metastases shortly after local therapy; Cohort 2: men with early progression to castration-resistant PCa in ≤ 1 year on ADT ± docetaxel or ADT ± abiraterone. Clinical and environmental history, peripheral blood for cell free DNA and germline analysis will be collected. Primary/metastatic tumor tissue will be tested via the Tempus platform, which includes DNA sequencing, whole transcriptome expression profiling, copy number analysis, comprehensive fusion gene analysis and calculation of tumor mutational burden. We will also prospectively correlate clinical and molecular characteristics with outcomes. To date, 5 patients have been registered.
In This Issue
Journal: Journal of Clinical Investigation (2012)

Sinking your teeth into the problem of spinal cord injuryThere is no proven reparative treatment for spinal cord injury (SCI), one of the most common causes of disability in young adults.Developing such a treatment will be hard because repair of SCI requires a multifaceted therapy that promotes axonal regeneration, remyelination, and formation of new synaptic connections.In seeking to rise to the challenge, Sakai and colleagues have found that transplantation of human tooth-derived stem cells into completely transected adult rat spinal cord leads to marked recovery of hind limb function (80-90).Importantly, the tooth-derived stem cells mediated their beneficial effects in several ways.First, they inhibited SCIinduced apoptosis of neurons, astrocytes, and oligodendrocytes (the myelin-forming cells of the CNS).Second, they promoted axonal regeneration by antagonizing inhibitors of axon growth.Last, they replaced lost cells by differentiating into mature oligodendrocytes.The fact that the human tooth-derived stem cells promoted functional recovery in a rat model of SCI via multiple neuroregenerative activities leads the authors to suggest that these cells might provide therapeutic benefit to individuals who have experienced SCI.
Notes/News
Journal: Annals of the Rheumatic Diseases (1996)

This course, to be held on 7-10 September 1996, Oxford, UK, will cover the biology of connective tissues, cell-to-cell interactions, immune responses and their control, mech- anisms of damage, and pathogenesis of rheumatic diseases.Course fee, including accommodation: £250. 3rd EULAR Postgraduate Course in RheumatologyThis course, to be held on 11-15 September 1996, Oxford, UK, will cover clinical aspects of rheumatic diseases concen- trating on outcome, assessment, and evidence based manage- ment.It is complementary to the 1st and 2nd EULAR Postgraduate Courses in Rheumatology held in Leuven (Belgium) in 1993 and in Marseilles (France) in 1994.The course is aimed at junior rheumatologists from throughout Europe at the end of their training (at least four years of postgraduate training), but is open to all rheumatologists.Course fee, including accommodation: £400.
La traviata
Authors: A. C. Barnes
Journal: JAMA (1969)

The physician who attends the opera<i>La Traviata</i>is likely to be disturbed by the practice of medicine shown in the last act. The heroine, Violette Valery, is dying of tuberculosis. In the first place, notes the physician in the audience, she is far too buxom and stout to have terminal pulmonary disease. Dr. Grenvil arrives carrying flowers and proceeds to sit familiarly on her bed. After these lapses in professional behavior, he fails to feel her pulse, or listen to her lungs or even to take her temperature. He assists her in getting out of bed (admittedly it is difficult to hit high C recumbent beneath a feather bolster, but this is no way to treat serious pulmonary tuberculosis). Finally he kisses Violetta on the forehead (questionable ethics and very bad hygiene), then he announces to the maid Annina—in a fine bass which easily reaches the back rows of
BOOK REVIEWS
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article BOOK REVIEWS Get access Wintrobe's Clinical Hematology, Ninth Edition, Vols. I&II . G. Richard Lee , Thomas C. Bithell , John Foerster , John W. Athens , John N. Lukens , eds. Philadelphia : Lea & Febiger , 1993 . 2401 pp., illus. $165. Reviewed by Alison Moliterno [J Natl Cancer Inst 85: 1600,1993] JNCI: Journal of the National Cancer Institute, Volume 86, Issue 3, 2 February 1994, Pages 235–236, https://doi.org/10.1093/jnci/86.3.235-d Published: 02 February 1994
Undergraduate medical education
Authors: A. E. Crowley
Journal: JAMA (1983)

<h3>MEDICAL SCHOOLS</h3><h3>Accreditation</h3> The official accrediting body for educational programs leading to the MD degree is the Liaison Committee on Medical Education (LCME), which is listed for this purpose by the US Secretary of Education and recognized by the Council on Postsecondary Accreditation. (For membership in the LCME, see Appendix I). The criteria by which the LCME accredits such programs in the United States, and in Canada in cooperation with the Committee for the Accreditation of Canadian Medical Schools (CACMS), are published in two separate but related documents: "Functions and Structure of a Medical School" and "Special Criteria for Programs in the Basic Medical Sciences." Copies of these documents are available from the LCME Office, 535 N Dearborn St, Chicago, IL 60610, or 1 Dupont Circle NW, Washington, DC 20036. <h3>Accredited Programs in Medical Education</h3> As of Sept 1, 1983, there were 124 US programs and 16 Canadian programs fully
Bioequivalence of Levothyroxine Preparations: Issues of Science, Publication, and Advertising-Reply
Authors: Michael T. Bramblett
Journal: JAMA (1997)

<h3>In Reply.</h3> —Dr Lankin seems to be under the impression that Levoxyl is a relatively unknown, underadvertised drug. To the contrary, of the top 200 prescribed drugs in the United States in 1996, Levoxyl was the 51st most often prescribed, up from 63rd in 1995.<sup>1</sup>The same Levoxyl ad that appeared in the April 16, 1997, issue of<i>JAMA</i>comparing the price benefit between Levoxyl and Synthroid has appeared in<i>Drug Topics, US Pharmacist, Journal of Clinical Endocrinology &amp; Metabolism, Endocrine Practice, Thyroid</i>, and<i>PA Today</i>for the past 2 years. Jones Medical Industries Inc is a public company that manufactures and markets pharmaceutical products. Yes, we do want to inform investors and prescribers about our company and the products we market. Consequently, our stock symbol appears on all public literature and advertisements. Obviously, Jones Medical Industries and Knoll Pharmaceutical were both notified of the publication date of the study conducted
Heart Size
Authors: Vincent Quagliarello
Journal: Annals of Internal Medicine (2018)

On Being a Doctor17 April 2018Heart SizeVincent Quagliarello, MDVincent Quagliarello, MDYale University School of Medicine, New Haven, Connecticut (V.Q.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M17-3201 Audio Reading - “Heart Size” Audio. Virginia L. Hood, MD, reads "Heart Size," by V. Quagliarello. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail You wake up and rush to work: the toilet, sink, shower, dress, coffee sequence. Morning rounds begin at 7:30, and you can't be late. You navigate traffic as you scan e-mails and text messages on your cell phone despite all warnings and a previous summons—$300 and a tongue-lashing from a state trooper. You drive off the highway toward the parking garage, and there's a man standing on the curb holding a brown cardboard sign. It usually says something like “please give,” “need food,” or “homeless veteran” printed in black marker so that the minimal contrast of the black on brown ... Author, Article, and Disclosure InformationAffiliations: Yale University School of Medicine, New Haven, Connecticut (V.Q.)Corresponding Author: Vincent Quagliarello, MD, Department of Internal Medicine, PO Box 208056, Yale University School of Medicine, New Haven, CT 06520-8056; e-mail, vincent.[email protected]edu. PreviousarticleNextarticle Advertisement Audio Reading - “Heart Size” Audio. Virginia L. Hood, MD, reads "Heart Size," by V. Quagliarello. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 17 April 2018Volume 168, Issue 8Page: 598KeywordsCoffeeCombined antiretroviral therapyFoodHeartPregnancyRacial and ethnic issuesSexual identityTouchUrineWalking ePublished: 17 April 2018 Issue Published: 17 April 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
SCROFULOSIS.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MISCELLANEA MEDICA
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Arthritis. The roles of the primary-care physician and the radiologist
Authors: J. Edeiken
Journal: JAMA (1975)

THE PRIMARY-CARE physician is usually the first to examine a patient with arthritis. He may not appreciate the seriousness of the disease, since its onset may be insidious, the symptoms trivial, and the roentgenographic changes absent. Roentgenograms of a joint are really inadequate for visualizing the structures primarily involved in arthritis. The "joint space" is not a space at all, but contains the cartilage and synovia. Since the density of these structures approaches water density, their morphologic state cannot be discerned roentgenologically, and inflammation and destruction may be invisible. Thus, symptoms and clinical findings may long antedate the roentgenographic changes. After sufficient cartilaginous destruction has occurred, the joint finally narrows. The decreased joint space may be the first roentgenographic sign of the disease, but by this time irreparable damage has been done. Secondary erosive destruction of the adjacent bone also occurs at a late stage. Conversely, in some patients roentgenographic
Chemical and Biological Investigations of a Transformer Accident at Binghamton, NY
Authors: Patrick W. O'Keefe, Jay B. Silkworth, John F. Gierthy, Robert M. Smith, Anthony P. DeCaprio, James N. Turner, George Eadon, David R. Hilker, Kenneth M. Aldous, Laurence S. Kaminsky, Doris N. Collins
Journal: Environmental Health Perspectives (1985)

A transformer fire occurred in a state office building in Binghamton, NY on February 5, 1981. Particulates from inside surfaces of ceiling panels on 16 of the 17 floors had concentrations of polychlorinated dibenzofurans (PCDFs) ranging from < 1 part per million (ppm) to 1200 ppm while polychlorinated biphenyl (PCB) concentrations varied from 28 ppm to 23,000 ppm. In spite of the wide variations in contaminant concentrations, complete analytical data from 11 floors showed that there was a consistent PCDF/PCB ratio (0.067 ± 0.026) and also consistent PCDF isomer group distributions (tetra-CDFs, 33 ± 5%; penta-CDFs, 40 ± 3%; hexa-CDFs, 18 ± 7%; hepta-CDFs, 6 ± 3%). It was found that the particulate samples could be successfully ranked in order of their degree of chemical contamination by an in vitro bioassay. The bioassay was based on induction of keratinization or changes in morphology in mouse epithelial cells. Animal toxicology experiments were carried out with a soot sample containing a PCDF concentration which approximated the mean value found on the ceiling particulates. The single dose oral LD values of the soot and its benzene extract equivalent, each administered to female guinea pigs in 0.75% methyl cellulose, were 410 and 327 mg/kg, respectively. These results demonstrated that the soot matrix had virtually no effect on the toxicity of the chemical contaminants in the soot. Morphological alterations in liver tissues from animals receiving the soot were found after examination by electron and light microscopy. Rabbits dermally exposed to the soot and its benzene extract at 500 mg/kg showed evidence of hypertrophy of centrilobular hepatocytes. In addition the rabbits exposed to the soot extract had a local inflammatory reaction at the site of application. In a subchronic feeding experiment carried out for 90 days with guinea pigs, the lowest effect level was found with an accumulated dose of 1.2 mg soot/kg. The observed effects included salivary gland duct metaplasia and decreased relative thymus weights. Based on the chemical analysis data and literature LD values for the more toxic 2,3,7,8-substituted polychlorinated dibenzo-p-dioxins (PCDDs) and PCDFs, it was calculated that the soot contained the equivalent of 44 ppm 2,3,7,8-tetra-CDD in terms of toxicity to guinea pigs. This was in close agreement with the value of 58 ppm derived from the acute oral toxicity experiments. Air sampling, accomplished on 8 floors in the final stages of the building cleanup, showed maximum total PCDF and 2,3,7,8-tetra-CDF concentrations of 264 and 23 pg/m, respectively.
08.11 The go-dact protocol: a randomised controlled trial to compare the efficacy of golimumab in combination with methotrexate (mtx) versus mtx monotherapy, in improving dactylitis and enthesitis, in mtx naïve psoriatic arthritis patients
Authors: Elsa Vieira-Sousa, Helena Canhão, João Eurico Fonseca
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Dactylitis is a hallmark manifestation of psoriatic arthritis (PsA) and a key feature for PsA diagnosis. Active dactylitis is associated with a higher risk of erosions and can severely impact function. The therapeutic strategies for dactylitis are however largely empirical, with a profound absence of knowledge regarding efficacy, as primary endpoint, and impact on disease progression. The use of biologic DMARDs in patients with dactylitis, refractory to NSAIDs or local corticosteroids, is recommended by EULAR guidelines, over the use of conventional DMARDs, based in the scarcity of evidence and properly designed studies in this field. <h3>Methods</h3> GO-DACT is an ongoing multicentric trial, involving 13 national Rheumatology departments. Patients older than 18 years, with the diagnosis of PsA and active dactylitis (tenderness score ≥1), refractory to NSAIDs, for 3 months, were included. Patients were randomised on a 1:1 ratio, to either MTX in combination with golimumab or placebo, for a period of 24 weeks. The primary aim of this trial is to determine differences of efficacy between the two treatment arms, in improving dactylitis (and enthesitis), as assessed by the Dactylitis Severity Score (DSS) at 24 weeks. Key secondary outcomes include: LDI, LEI, joint counts, PASI and NAPSI, HAQ, DLQI and composite indexes for disease activity. The effect of treatment arms, on different tissue compartments, will be analysed by contrast-enhanced MRI, with high resolution images for dactylitis, at baseline and 24 weeks. <h3>Conclusions</h3> The results from GO-DACT are expected to have implications in clinical practice, bringing robust and valid data for the definition of dactylitis treatment stratification and algorithm. GO-DACT will also contribute to understand dactylitis pathogenesis through the assessment of treatment efficacy, namely in distinct tissue compartments as defined by MRI. https://www.clinicaltrials.gov (NCT02065713)
Exercise on prescription for women aged 40-74 recruited through primary care: two year randomised controlled trial
Journal: BMJ (2009)

Objective To assess the effectiveness of a primary care based programme of exercise on prescription among relatively inactive women over a two year period.Design Randomised controlled trial.Setting 17 primary care practices in Wellington, New Zealand Participants 1089 women aged 40-74 not undertaking 30 minutes of moderate intensity physical activity on at least five days of the week Intervention Brief physical activity intervention led by nurse with six month follow-up visit and monthly telephone support over nine months.Main outcome measure Physical activity assessed at baseline and 12 and 24 months.Secondary outcomes were quality of life (SF-36), weight, waist circumference, blood pressure, concentrations of fasting serum lipids, glycated haemoglobin (HbA 1c ), glucose, insulin, and physical fitness.Results Mean age was 58.9 (SD 7) years.Trial retention rates were 93% and 89% at 12 and 24 months, respectively.At baseline, 10% of intervention participants and 11% of control participants were achieving 150 minutes of at least moderate intensity physical activity a week.At 12 months rates increased to 43% and 30% and at 24 months to 39.3% and 32.8% (P<0.001),respectively.SF-36 physical functioning (P=0.03) and mental health (P<0.05)scores improved more in intervention compared with control participants, but role physical scores were significantly lower (P<0.01).There were no significant differences in clinical outcomes.More falls (P<0.001) and injuries (P=0.03) were recorded in the intervention group.Conclusions This programme of exercise on prescription increased physical activity and quality of life over two years, although falls and injuries also increased.This finding supports the use of exercise on prescription programmes as part of population strategies to reduce physical inactivity.
Photodynamic therapy with local verteporfin delivery reduces stent-induced intimal thickening Douglas E. Drachman, Gregory S. Toegel, Stefan G. Hesselberg, William R. Tyrrell, Jr., Adam R. Groothuis, Russell G. Hodge, Richard T. Choh, Kristina A. Arnold, Campbell Rogers. Brigham and Women's Hospital, Boston, MA, Massachusetts Institute of Technology, Cambridge, MA
Journal: Journal of the American College of Cardiology (2001)
A phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with locally advanced rectal cancer (LARC): Long-term results
Authors: C. Qvortrup, A. Jakobsen, F. Hansen, G. Baatrup, C. Bisgaard, P. Rasmussen, P. Pfeiffer
Journal: Journal of Clinical Oncology (2004)

3590